NYSE:NVOPharmaceuticals
Novo Nordisk’s Thalassemia Push Adds Rare Blood Upside To Valuation
Novo Nordisk (NYSE:NVO) is progressing etavopivat, a therapy candidate for thalassemia, in its rare blood disorders pipeline.
The company is pairing this clinical work with regulatory activities in key markets, signaling a push into hematology.
This move comes as most recent investor focus has centered on obesity care and Alzheimer’s disease programs.
Novo Nordisk is widely associated with obesity and diabetes treatments, and more recently with interest around Alzheimer’s disease research...